Immunostimulatory effect of Silybum Marianum (milk thistle) extract

Medical Science Monitor

Volumn 8, Issue 11, 2002, Pages

  Wilasrusmee, Chumpon ^a   Kittur, Smita ^a   Shah, Gaurang ^a   Siddiqui, Josephine ^a   Bruch, David ^a   Wilasrusmee, Skuntala ^a   Kittur, Dilip S ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Alloantigen; Immune system; Mitogen stimulation; Mixed lymphocyte culture

Indexed keywords

CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; MITOGENIC AGENT; SILYBUM MARIANUM EXTRACT; ALLOANTIGEN; CYTOKINE; PLANT EXTRACT;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE SYSTEM; IMMUNITY; IMMUNOSTIMULATION; INFECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; TH1 CELL; TH2 CELL; ANIMAL; C57BL MOUSE; CELL DIVISION; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; LYMPHOCYTE; MEDICINAL PLANT; METABOLISM; PHYSIOLOGY; SILYBUM MARIANUM;

ANIMALS; CELL DIVISION; CONCANAVALIN A; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNE SYSTEM; ISOANTIGENS; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MILK THISTLE; MITOGENS; PLANT EXTRACTS; PLANTS, MEDICINAL;

EID: 4644339400     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Eisenberg DM, Kessler RC, Foster C et al: Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med, 1993; 328(4): 246-252
2. Astin JA: Why patients use alternative medicine: Results of a national study. JAMA, 1998; 279(19): 1548-1553
3. Brevoort P: The U. S. Botanical market - An overview. Ref Type: Generic, Herbalgram, 2001; 36: 49-57
4. Johnson EM, Wootton JC, Kimzey R et al: Use of herbal therapies by adults seen in an ambulatory care research setting: An explorato ry survey. J Altern Complement Med, 2000; 6(5): 429-435.
5. Flora K, Hahn M, Rosen H, Benner K: Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol, 1998; 93(2): 139-143
6. Gaedeke J, Fels LM, Bokemeyer C et al: Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant, 1996; 11(1): 55-62
7. Quaglia MG, Bossu E, Donati E et al: Determination of silymarine in the extract from the dried silybum marianum fruits by high performance liquid chromatography and capillary electrophoresis. J Pharm Biomed Anal, 1999; 19(3-4): 435-442
8. Scambia G, De Vincenzo R, Ranelletti FO et al: Antiproliferative effect of silybin on gynaecological malignancies: Synergism with cisplatin and doxorubicin. Eur J Cancer, 1996; 32A(5): 877-882
9. Velussi M, Cernigoi AM, De Monte A et al: Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol, 1997; 26(4): 871-879
10. Venkataramanan R, Ramachandran V, Komoroski BJ et al: Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos, 2000; 28(11): 1270-1273
11. von Schonfeld J, Weisbrod B, Muller MK: Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity. Cell Mol Life Sci. 1997; 53(11-12): 917-920
12. Zhao J, Sharma Y, Agarwal R: Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorhol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1alpha expression in SENCAR mouse epidermis: Implications in the prevention of stage I tumor promotion. Mol Carcinog. 1999; 26(4): 321-333
13. Saller R, Meier R, Brignoli R: The use of silymarin in the treatment of liver diseases. Drugs, 2001; 61(14): 2035-2063
14. Zi X, Agarwal R: Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention. Proc Natl Acad Sci USA, 1999; 96(13): 7490-7495
15. Lahiri-Chatterjee M, Katiyar SK, Mohan RR, Agarwal R: A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res, 1999; 59(3): 622-632
16. Zi X, Feyes DK, Agarwal R: Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: Induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin Cancer Res, 1998; 4(4): 1055-1064
17. Valenzuela A, Aspillaga M, Vial S, Guerra R: Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta Med, 1989; 55(5): 420-422
18. Sonnenbichler J, Scalera F, Sonnenbichler I, Weyhenmeyer R: Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther, 1999; 290(3): 1375-1383
19. Soliman KF, Mazzio EA: In vitro attenuation of nitric oxide production in C6 astrocyte cell culture by various dietary compounds. Proc Soc Exp Biol Med, 1998; 218(4): 390-397
20. Tager M, Dietzmann J, Thiel U et al: Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the flavonoids silibinin and silymarin. Free Radic Res, 2001; 34(2): 137-151
21. Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB: Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N- terminal kinase, and apoptosis. J Immunol, 1999; 163(12): 6800-6809